P261. Clinical usefulness of fecal calprotectin measurement in predicting intestinal involvement of Behçet's disease: preliminary results
D.H. Kim, B. Kim, S.J. Park, S.P. Hong, T.I. Kim, W.H. Kim, J.H. Cheon, Yonsei University College of Medicine, Department of Internal Medicine and Institute of Gastroenterology, Seoul, South Korea
Fecal calprotectin (FC) concentration directly represents the degree of intestinal inflammation. It is established that FC level predicts the clinical course of inflammatory bowel disease. However, little is known about the impact of FC in patients with intestinal Behçet's disease (BD).
Fifteen consecutive patients with systemic BD who undertook colonoscopy for evaluation of gastrointestinal symptoms were prospectively enrolled between November, 2012 and March, 2013 in Severance hospital, Seoul, Korea. Fecal specimens from the patients were obtained one day before starting bowel preparation. FC level was compared with colonoscopic outcomes, disease activity index for intestinal BD (DAIBD), and laboratory markers.
Median age of the patients was 43 (31–68) and nine (60%) were male. Of them, 11 (73.3%) showed intestinal ulcers (five typical and six atypical ulcers). Terminal ileum was the most frequent location (81.8%). Three definite intestinal BD (27.3%) and eight probable intestinal BD (72.7%) were diagnosed from the established criteria. Median FC level in patients who had typical intestinal ulcers was significantly higher than in those with atypical ulcers or without ulcers (567.83 µg/g (327.12–1604.39), 51.75 µg/g (20.14–95.18) and 58.36 µg/g (6.04–103.53), respectively; P = 0.004 and 0.016, respectively). However, serum CRP level and DAIBD in patients with typical ulcers were not significantly different from those in patients with atypical ulcers or without ulcers.
High FC level was clearly correlated with typical intestinal BD ulcers. FC level might have a significant role as a non-invasive surrogate marker of intestinal involvement of BD.